A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma

Protocol: 
AAAR5002
Phase: 
II

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma

Are you Eligible? (Inclusion Criteria)

Participants must be able to give consent, willing and able to comply with
scheduled treatments, and provide consent for 3 mandatory tumor biopsy
samples

All participants must have:
- advanced or metastatic RCC (renal cell carcinoma)
- prior treatment with IL-2, INF or radiotherapy that ended 4 weeks prior to
randomization

Specialty Area(s)